$38.54
1.76% yesterday
Nasdaq, Apr 23, 10:06 pm CET
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

CRISPR Therapeutics AG Stock price

$38.54
-4.08 9.57% 1M
-7.46 16.22% 6M
-0.82 2.08% YTD
-17.87 31.68% 1Y
-18.73 32.70% 3Y
-13.94 26.56% 5Y
+24.45 173.53% 10Y
Nasdaq, Closing price Wed, Apr 23 2025
-0.69 1.76%
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

Key metrics

Market capitalization $3.32b
Enterprise Value $1.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 44.00
P/S ratio (TTM) P/S ratio 89.03
P/B ratio (TTM) P/B ratio 1.71
Revenue growth (TTM) Revenue growth -89.95%
Revenue (TTM) Revenue $37.31m
EBIT (operating result TTM) EBIT $-466.57m
Free Cash Flow (TTM) Free Cash Flow $-144.68m
Cash position $1.90b
EPS (TTM) EPS $-4.36
P/E forward negative
P/S forward 58.30
EV/Sales forward 28.81
Short interest 27.08%
Show more

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,783 stocks worldwide.

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a CRISPR Therapeutics AG forecast:

16x Buy
55%
12x Hold
41%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
55%
Hold
41%
Sell
3%

Financial data from CRISPR Therapeutics AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
37 37
90% 90%
100%
- Direct Costs 130 130
2% 2%
347%
-92 -92
138% 138%
-247%
- Selling and Administrative Expenses 54 54
5% 5%
144%
- Research and Development Expense 301 301
18% 18%
808%
-447 -447
149% 149%
-1,199%
- Depreciation and Amortization 19 19
3% 3%
52%
EBIT (Operating Income) EBIT -467 -467
134% 134%
-1,251%
Net Profit -366 -366
138% 138%
-982%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Neutral
The Motley Fool
4 days ago
A "monster stock" might be one that frightens you by free-falling. Or it might alarm you with characteristics such as plummeting sales, shrinking profit margins, or surging debt.
Positive
The Motley Fool
12 days ago
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.
Positive
The Motley Fool
13 days ago
Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities.
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Samarth Kulkarni
Employees 393
Founded 2013
Website www.crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today